SINGAPORE, June 26 (Reuters) - Saudi Aramco resumed oil loading on Friday at its Ras Tanura terminal in the Gulf after a near four-month halt, shipping data from LSEG showed. Two Very Large Crude ...

Treasury yields are little changed after a largely as-expected inflation reading. Core prices rose 0.2% in May from the previous month, slightly below expectations for a 0.3% increase. But the 2.9% ...

The U.S. 10-year Treasury yield held steady Wednesday as investors pored through the latest data showing inflation last month at its highest in three years, though some pricing pressures weren't as ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 ...

Colorado rafting and angling guides are reporting a steady flow of customers, despite low stream flows, as the summer recreation season kicks off on the Arkansas River — one of the most popular ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

Florida-Based AP Governance Firm Selected as RFP-Stage Contender, Reinforcing Its Authority in Enterprise SAP Vendor Master Data Compliance and Modernization PORT ST. LUCIE, Fla., May 10, 2026 / PRZen ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...